Astellas also revealed today that it is terminating the development of ASP2390, a DNA vaccine for house dust mite-induced allergic rhinitis, and GITR agonist antibody ASP1951 for cancer – both ...

Astellas' gastric cancer therapy gets UK ... as it looks to expand its drug pipeline and research base in the Boston area. Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief strategy officer said. Mitsubishi Tanabe Pharma is being sold to Bain Capital ...